“The Company continues to achieve key milestones for our prospective ExoPTEN drug and the development of an exosome-based therapy platform to be potentially used to achieve functional recovery in acute injuries related to the central nervous system,” said Dr. Lior Shaltiel, CEO of NurExone. “We believe that the advancements made in recent studies and collaborations puts us on the path to make further discoveries that can advance our research and development efforts and enhance our proprietary exosome-based products.”